Biogen (BIIB) PT Lowered to $343 at Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $253.84 +1.97%
Rating Summary:
31 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
31 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Wells Fargo analyst Mohit Bansal lowered the price target on Biogen (NASDAQ: BIIB) to $343.00 (from $350.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $300 at Guggenheim
- Wayfair (W) PT Raised to $160 at Truist Securities
- Livanova (LIVN) PT Raised to $115 at Mizuho
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
